Beruflich Dokumente
Kultur Dokumente
Chan et al.
Femoral Fractures and Alendronate Therapy
Musculoskeletal Imaging
Clinical Perspective
Subtrochanteric Femoral
Downloaded from www.ajronline.org by 125.163.237.33 on 03/12/17 from IP address 125.163.237.33. Copyright ARRS. For personal use only; all rights reserved
A
lendronate sodium (alendronate) receiving long-term alendronate therapy was per-
is a bisphosphonate that has been formed. The fractures occurred in 22 patients, 12
extensively and successfully used of whom suffered bilateral fractures. Twenty of
for the treatment of osteoporosis these patients were seen at our orthopedic depart-
[1–3]. The mechanism of action involves the ment, and two patients were referred for imaging
induction of osteoclast apoptosis, thereby re- during a 4-year period. All patients were women
ducing bone resorption [4]. Recently, several (age range, 50–81 years; mean age, 64 years).
studies have reported an increased prevalence The patients had received alendronate therapy for
of low-energy subtrochanteric femoral frac- a minimum of 4 years and up to 14 years (mean,
tures in patients receiving long-term alen- 6 years). All patients reported no or minor trau-
dronate therapy [5–13]. Studies have also re- ma. The imaging studies included radiography
ported an association between the use of (n = 34), bone scintigraphy (n = 4), CT (n = 4),
bisphosphonates and osteonecrosis of the jaw and MRI (n = 5). For the complete fractures, the
[14, 15]. The pathogenesis of these complica- bone scintigraphy and the cross-sectional studies
tions is not fully understood but may be relat- were performed to exclude underlying pathologic
ed to osteoclast inhibition and the resulting processes, in view of the lack of significant
suppression of bone turnover and bone re- trauma; for the incomplete fractures, the studies
modeling, leading to atypical skeletal fragility were performed to further assess the cause for
Keywords: alendronate, fracture, trauma
[16–20]. The significance of recognizing this hip pain. For one patient with incomplete frac-
type of fracture is paramount. In our experi- ture, MRI was performed to exclude an osteoid
DOI:10.2214/AJR.09.3588 ence, the number of these types of fractures osteoma, suspected on radiographs; for the other
continues to increase and the clinical implica- patients, MRI was performed to evaluate the cause
Received September 6, 2009; accepted after revision
tions and importance of fractures reported in of continued pain.
November 17, 2009.
women receiving long-term bisphosphonates Two musculoskeletal radiologists, one with 20
1
Department of Radiology, New York University Hospital cannot be understated. This study focuses on years and one with 1 year of musculoskeletal radi-
for Joint Diseases, 301 E 17th St., 6th Fl., New York, NY the imaging findings in a series of patients re- ology experience, reviewed the studies in consen-
10009. Address correspondence to S. S. Chan ceiving long-term alendronate therapy who sus. The following fracture characteristics were
(sarahshockchan@gmail.com).
experienced proximal femoral fractures. recorded: complete or incomplete fracture, dis-
2
Department of Orthopedics, New York University tance from lesser trochanter, fracture orientation,
Hospital for Joint Diseases, New York, NY. Materials and Methods alignment, presence of associated lateral cortical
Institutional review board approval was ob- thickening, and time to complete healing. When
AJR 2010; 194:1581–1586 tained, and informed consent was waived for this additional imaging techniques were used, the re-
0361–803X/10/1946–1581
retrospective HIPAA-compliant study. viewers also reviewed those studies in consensus,
A retrospective review of the imaging findings with knowledge of the radiographic findings. In the
© American Roentgen Ray Society in 34 proximal femoral fractures in 22 patients case of CT scans, the same fracture characteristics
Discussion
Alendronate was the first oral bisphos-
phonate available in the United States for
the treatment of osteoporosis. It has been
proven in randomized controlled studies to
significantly reduce the risk of osteoporotic
fractures and to increase bone mineral den-
sity [1–3]. Thus, the paradoxical association
of low-energy subtrochanteric femoral frac-
tures associated with long-term (defined in
this series as ≥ 4 years) alendronate thera-
py is an unexpected and only recently recog-
nized phenomenon.
Alendendronate induces osteoclast apop-
tosis, thereby inhibiting osteoclast-mediat-
ed bone resorption. Although osteoclast in-
hibition will increase bone mineral density,
in the long term, it can lead to abnormal
bone remodeling and repair, allowing bone
microdamage and atypical skeletal fragil-
ity [16–20]. This process will increase the
fracture risk in some patients. Cheung et
al. [10] described the findings on bone bi-
opsy for a patient who sustained a low-en-
ergy alendronate-related femoral fracture.
A B The histologic specimen depicted depressed
Fig. 6—56-year-old woman with chronic left leg pain. bone formation and marked reduction in os-
A and B, Images show progression of incomplete fracture involving lateral femoral cortex, with increased
amount of cortical thickening and enlargement of fracture lucency. Radiograph in A was obtained almost 2
teoid thickness and volume. Although 40%
years before radiograph in B. (B is reprinted with permission from The Journal of Bone and Joint Surgery [13]) of the trabecular surface was covered with
A B C
Fig. 10—66-year-old woman with leg pain.
A and B, Coronal T2-weighted (a) and T1-weighted (b) fat-suppressed MR images of right femur from outside institution show intramedullary edema and lateral cortical
thickening. Diagnosis of stress fracture was made.
C, Anteroposterior radiograph of right femur obtained at our institution 1 month later shows development of complete fracture.
seven cases required additional cross-sec- tramedullary nail fixation, as would conven- alendronate therapy who present with hip or
tional studies (CT or MRI) to arrive at the tional subtrochanteric traumatic fractures. femoral pain, imaging, primarily with radi-
correct diagnosis or to exclude a pathologic At our institution, the orthopedic surgeons ography and perhaps with MR, should cer-
fracture. Also, four patients underwent bone generally recommend prophylactic operative tainly be performed.
scanning, in one case to exclude metastatic treatment of incomplete fractures, to avoid The association of proximal femoral frac-
disease (in the setting of a complete fracture) progression to complete fractures. In addi- tures with long-term alendronate therapy re-
and in three cases to confirm the presence of tion, given the high number of patients who quires future extensive study. At present, there
an incomplete fracture. suffer bilateral factures, radiographs of the is no consensus on the appropriate duration of
Unlike a few reports in the literature [16], contralateral femur are recommended for pa- alendronate therapy in osteoporotic patients
our patients had a fairly typical healing tients receiving long-term alendronate ther- and, more specifically, in patients with associ-
course not significantly different from that of apy who present with a subtrochanteric or ated proximal femoral fractures. Also, it is
other patients with traumatic proximal femo- diaphyseal femur fracture. If a contralater- unknown whether the association with low-
ral fractures, with all but one of the fixated al stress fracture is found, prophylactic fixa- energy subtrochanteric fractures holds true
fractures healing within 6 months. However, tion of the femur should also be considered for all classes of bisphosphonates or is limited
in one case of incomplete fracture that was [13]. Furthermore, our clinical colleagues at solely to alendronate therapy, because most
monitored for 2 years before fixation, the our institution think that alendronate therapy studies to date have focused on alendronate.
fracture did not heal with time and protected should be discontinued, at least temporarily, Two case reports have been published that de-
weightbearing. in patients with proximal femoral fractures scribe similar fractures in patients receiving
Given the relatively new phenomenon of that are characteristic of those associated zoledronic acid (Zometa, Novartis) and rise-
proximal femoral fractures associated with with alendronate. Therefore, familiarity with dronate sodium (Actonel, Procter & Gamble
alendronate therapy, no globally accepted the characteristic clinical and imaging fea- Pharmaceuticals) [23, 24]. The question wheth-
treatment has been established, but in our tures of these fractures, whether complete or er IV infusion is a more potent form of bisphos
experience and in other case reports [8, 12], incomplete, is crucial for appropriate clinical phonate, which may lead to an increased prev-
these fractures are typically treated with in- management. In patients receiving long-term alence of fractures as compared with the oral
bisphosphonates, is also unknown. This is the fracture in women with existing vertebral frac- 2006; 61:31–33
case with osteonecrosis of the jaw. Further- tures: Fracture Intervention Trial Research Group. 13. Capeci CM, Tejwani NC. Bilateral low-energy
more, it is unclear which category of patients Lancet 1996; 348:1535–1541 simultaneous or sequential femur fractures in pa-
is more susceptible to the development of 2. Black DM, Thompson DE, Bauer DC, et al. Frac- tients on long-term alendronate therapy. J Bone
proximal femoral fractures and what clinical ture risk reduction with alendronate in women Joint Surg Am 2009; 91:2556–2561
markers may herald the onset of these frac- with osteoporosis: Fracture Intervention Trial Re- 14. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al.
Downloaded from www.ajronline.org by 125.163.237.33 on 03/12/17 from IP address 125.163.237.33. Copyright ARRS. For personal use only; all rights reserved
tures. Regardless, the association of alen- search Group. J Clin Endocrinol Metab 2000; Osteonecrosis of the jaws associated with the use
dronate with femoral fractures indicates that 85:4118–4124 of bisphosphonates: a review of 63 cases. J Oral
greater caution is required in the administra- 3. Bone HG, Hosking D, Devogelaer JP, et al. Ten Maxillofac Surg 2004; 62:527–534
tion and monitoring of bisphosphonate thera- years’ experience with alendronate for osteoporo- 15. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws
py. Familiarity with the characteristic clinical sis in postmenopausal women. N Engl J Med and bisphosphonate therapy. J Dent Res 2007;
and imaging features of these fractures, 2004; 350:1189–1199 86:1013–1021
whether complete or incomplete, is also cru- 4. Luckman SP, Hughes DE, Coxon FP, Russell 16. Visekruna M, Wilson D, McKiernan FE. Severely
cial for appropriate clinical management. RGR, Rogers MJ. Nitrogen-containing bisphos- suppressed bone turnover and atypical skeletal fragil-
The major limitations of our study are its phonates inhibit the mevalonate pathway and pre- ity. J Clin Endocrinol Metab 2008; 93:2948–2952
retrospective nature and small sample size. vent posttranslational prenylation of GTP-bind- 17. Mashiba T, Turner CH, Hirano T, Forwood C,
Also, we had limited access to the clinical in- ing proteins, including Ras. J Bone Miner Res Johnston C, Burr DB. Effects of suppressed bone
formation on the patients. It would have been 1998; 13:581–589 turnover by bisphosphonates on microdamage ac-
useful to correlate our findings with metabol- 5. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula cumulation and biomechanical properties in clini-
ic indexes, such as serum calcium level, phos- F, Lorich DG. Low-energy femoral shaft fractures cally relevant skeletal sites in beagles. Bone 2001;
phorus and alkaline phosphatase levels, bone associated with alendronate use. J Orthop Trauma 28:524–531
mineral density, and parathyroid hormone 2008; 22:346–350 18. Mashiba T, Mori S, Burr DB, et al. The effects
levels. Also, the use of other drugs that may 6. Kwek EBK, Goh SK, Koh JBS, Png MA, Howe of suppressed bone remodeling by bisphospho-
influence bone stock, such as hormone re- TS. An emerging pattern of subtrochanteric stress nates on microdamage accumulation and degree
placement therapy or steroids, was not known. fractures: a long-term complication of alendronate of mineralization in the cortical bone of a dog
Future prospective studies may be useful to therapy? Injury 2008; 39:224–231 rib. J Bone Miner Metab 2005; 23:36–42
assess the prevalence of these fractures in pa- 7. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric 19. Odvina CV, Zerwekh JE, Rao DS, Maalouf N,
tients receiving alendronate therapy. insufficiency fractures in patients on alendronate Gottschalk FA, Pak CYC. Severely suppressed
In conclusion, subtrochanteric femoral therapy: a caution. J Bone Joint Surg Br 2007; bone turnover: potential complication of alen-
fractures associated with alendronate thera- 89:349–353 dronate therapy. J Clin Endocrinol Metab 2005;
py have typical clinical and radiographic pat- 8. Sayed-Noor AS, Sjoden GO. Subtrochanteric dis- 90:1294–1301
terns. In complete fractures, these include mi- placed insufficiency fracture after long-term alen- 20. Armamento-Villareal R, Napoli N, Panwar V, No-
nor or no trauma, initial involvement of the dronate therapy: a case report. Acta Orthop 2008; vack D. Suppressed bone turnover during alen-
lateral proximal femoral cortex, transverse 79:565–567 dronate therapy for high-turnover osteoporosis. N
orientation, medial beak, skirt-like focal 9. Lenart BA, Lorich DG, Lane JM. Atypical frac- Engl J Med 2006; 355:2048–2050
thickening at the opposing lateral cortical sur- tures of the femoral diaphysis in postmenopausal 21. Krestan C, Hojreh A. Imaging of insufficiency
faces, superior displacement of the distal frag- women taking alendronate. N Engl J Med 2008; fractures. Eur J Radiol 2009; 71:398–405
ment, and varus angulation at the fracture site. 358:1304–1306 22. Spitz DJ, Newberg AH. Imaging of stress frac-
Incomplete fractures show focal lateral corti- 10. Cheung RKH, Leung KK, Lee KC, Chow TC. Se- tures in the athlete. Radiol Clin North Am 2002;
cal thickening with or without an incomplete quential non-traumatic femoral shaft fractures in 40:313–331
transverse fracture line. Familiarity with these a patient on long-term alendronate. Hong Kong 23. Bush LA, Chew FS. Subtrochanteric femoral in-
features will expedite detection and treatment Med J 2007; 13:485–489 suffiency fracture in woman on bisphosphonate
and alert the clinician to reconsider the risks 11. Iwamoto J, Takeda T. Insufficiency fracture of the therapy for glucocorticoid-induced osteoporosis.
and benefits of alendronate therapy. femoral neck during osteoporosis treatment: a Radiol Case Rep 2009; 4:1
case report. J Orthop Sci 2002; 7:707–712 24. Bush LA, Chew FS. Subtrochanteric femoral in-
References 12. Schneider JP. Should bisphosphonates be contin- suffiency fracture following bisphosphonate ther-
1. Black DM, Cummings SR, Karpf DB, et al. Ran- ued indefinitely? An unusual fracture in a healthy apy for osseous metastases. Radiol Case Rep
domised trial of effect of alendronate on risk of woman on long-term alendronate. Geriatrics 2008; 3:1–6